Filing Flows › Pacific Biosciences of California (PACB) › Q3 2025
Pacific Biosciences of California (PACB) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 6, 2025
Pacific Biosciences of California (PACB) reported revenue of $38.4M for the third quarter 2025 (Q3 2025), -4% from a year earlier and -3% from the quarter before. Operating margin was -101.1%, net loss $38.0M (98.9% of revenue).
Pacific Biosciences of California, Q3 2025: revenue $38.4M (-4% year over year), operating margin -101.1%, net loss $38.0M, operating cash flow −$18.7M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $38.4M | -3% | -4% |
| Operating profit | −$38.9M | — | — |
| Net earnings | −$38.0M | — | — |
| Operating cash flow | −$18.7M | — | — |
What changed
Revenue was $38.4M in Q3 2025, down 4% year over year and down 3% from the previous quarter. Consumable revenue was the largest line at 55% of revenue. Instrument revenue lost $5.5M year over year (down 33%), 358% of the total change.
Gross margin was 41.4%, up 16.3 points from a year earlier. Operating costs exceeded revenue by $38.9M, an operating margin of -101.1%. Operating expenses fell 26% while revenue fell 4%. The quarter ended with a net loss of $38.0M, narrower than the previous quarter's $41.9M loss.
Operating cash flow was −$18.7M. Non-cash charges added back $3.5M of depreciation and amortization and $11.0M of share-based compensation. Working capital and other items added $4.8M. Capital expenditures of −$86K exceeded it, leaving free cash flow of −$18.6M.
Questions
What was Pacific Biosciences of California's revenue in the third quarter 2025?
Pacific Biosciences of California (PACB) reported revenue of $38.4M for the third quarter 2025 (Q3 2025), -4% from a year earlier and -3% from the quarter before.
Was Pacific Biosciences of California profitable in the third quarter 2025?
Operating loss was $38.9M (-101.1% of revenue) and net loss $38.0M.
Source: Pacific Biosciences of California 10-Q on SEC EDGAR.